FUNDAMENTALS · Fundamentals · KR Healthcare

CG Invites (083790) Fundamentals 2026 — Revenue Analysis | SniperIQ

CG Invites (083790) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩63.3B, trading at ₩823.00 on the KOE. This SniperIQ fundamentals page covers CG Invites's valuation, profitability (net margin -11.3%), revenue (₩27.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩63.3B
Net Margin-11.3%
Revenue (FY25)₩27.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CG Invites's market cap?

CG Invites (083790) has a market capitalization of approximately ₩63.3B, trading at ₩823.00 on the KOE. Market cap moves with the live share price.

What is CG Invites's P/E ratio?

CG Invites's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CG Invites?

CG Invites runs a net profit margin of -11.3%, a gross margin of -32.0%, and an operating margin of -85.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CG Invites generate?

CG Invites reported revenue of ₩27.4B for fiscal year 2025, with net income of -₩3.5B and earnings per share (EPS) of -45.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CG Invites pay a dividend?

CG Invites does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CG Invites financially healthy?

CG Invites carries a debt-to-equity ratio of 0.46x and a current ratio of 0.46x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CG Invites a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CG Invites (083790) the key facts are: market cap ₩63.3B, revenue ₩27.4B, 52-week range 760-1985. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CG Invites's full fundamentals live

Get CG Invites's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: JCR Pharmaceuticals (4552) fundamentals · ASKA Pharmaceutical Holdings (4886) fundamentals · Boston Scientific (BSX) fundamentals · Kovai Medical Center and Hospital (KOVAI) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons